CLEW Receives FDA Emergency Use Authorization (EUA) for Its Predictive Analytics Platform in Support of COVID-19 Patients
TEL AVIV, Israel and WILMINGTON, Delaware, June 16, 2020 /PRNewswire/ -- CLEW announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company's ICU solution. With CLEWICU healthcare providers use predictive screening information to help identify patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability which are common complications associated with COVID-19.
The AI-based algorithms are machine-learning models trained to identify respiratory failure and or hemodynamic instability hours in advance. This allows for additional evaluation and potentially early intervention, planning, resource management.
CLEW's AI models were trained on nearly 100,000 patients in the ICUs, and scales to cope with patient volume surges while reducing a caregiver's exposure risk to infected patients.
CLEW's models were developed and intended for both local ICUs and TeleICUs and integrates best practice modules.
The streamlined at-a-glance web application is designed for near real-time access to patient data and provides tools for both worklist, unit and multiunit views, featuring unit occupancy and patient risk level.
CLEW-ICU integrates caregiving of local and remote teams enabling workflow and resource decision making.
"Healthcare providers need more than simple analytics. Systems need to integrate into the provider's workflow, offering ease of use and actionable data. The CLEWICU platform is designed to enable healthcare providers to monitor patient predicted risk levels across all units in real-time allowing for smart decision making about clinical resource allocation, ensuring prompt, proactive and efficient patient care," said Gal Salomon, CLEW CEO.
About CLEW:
CLEW provides real-time AI analytics platforms designed to help providers make better informed clinical decisions by predicting life-threatening complications across various medical care settings. CLEW's goal is to provide solutions that could improve outcomes and safety, streamline patient care, and efficiently handle regulations and penalties, ultimately lowering the cost of care. Originally developed and proven in the ICU, CLEW will develop machine learning models that have the potential to optimize clinical resources and guide health care providers in predicting patient deterioration, across all care settings.
Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that, further to its press release dated October 18, 2023, it has...
Autohome Inc. ("Autohome" or the "Company"), the leading online destination for automobile consumers in China, today announced that it will hold its annual general meeting of shareholders (the "AGM") at 18th Floor Tower B, CEC Plaza, 3 Dan Ling...
Avid Controls is an authorized licensed manufacturer of the GEPC/Converteam MV3000 product line, and is dedicated to providing world-class support to customers for the entire lifespan of their equipment. The MV3000 modules provide reliable ancillary...
MikeWorldWide, a leading New York-based, independent public relations agencies with offices across the US and UK has promoted Megan Hueter to lead digital practice and created two new vice president positions to strengthen functional expertise in...
TechTarget's Enterprise Strategy Group, a leading IT analyst, research, and strategy firm, today announced the addition of Jim Frey as Principal Analyst to lead the firm's coverage of the networking market. Frey will be covering networking and...
Ferrovial has teamed up with U.S. technology consulting firm DXC Technology to jointly develop the platform known as Quercus to accelerate and scale the adoption of Generative Artificial Intelligence (AI) across the infrastructure company's...